Eppendorf Announces It Has Received Connecticut State Approval to Conduct Biosafety Level 2 Infectious Disease Related Research

ME Newswire / Businesswire

ENFIELD, Conn - Monday, October 21st 2013

Eppendorf is proud to announce they have received Connecticut State approval to conduct Biosafety Level 2 (BL2) infectious disease related research. This greatly expands the capabilities of the Eppendorf Research and Development Laboratory located at their Enfield facility, and enhances research plans and activities for customers. “We plan to further our research in stem cell bioprocess to include induced pluripotent stem cells (IPSCs)” stated Dr. Ma Sha, Director, Technical Applications. “We are also actively seeking industry or industry/academia collaborations in the stem cell bioprocess area.”

The method involved in making the IPSC uses viruses to transfer reprogramming genes into regular cells, thus turning these cells into stem cells. These stem cells can then be used in clinical research for the treatment of disease or injury. There are hundreds of clinical trials using such cells listed at www.clinicaltrials.gov. The clinical trial market potential is large, and successful trials would then require the ability to scale up to industry production levels. The Eppendorf bioreactor portfolio, including the New Brunswick™ CelliGen® BLU, can be used to demonstrate large scale stem cell culture for industry production requirements.

Click here to learn more

http://newbrunswick.eppendorf.com New Brunswick Scientific newbrunswick@eppendorf.com

About Eppendorf

Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid, cell and sample handling. Today, Eppendorf and its 2,700 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world. Information about Eppendorf is available on the Internet at: www.eppendorf.com

Eppendorf® is a registered trademark of Eppendorf AG, Germany. New Brunswick™ is a pending trademark of Eppendorf AG, Germany. CelliGen® is a registered trademark of New Brunswick Scientific, Co, Inc., USA.

Contacts

Eppendorf

Thomas A. Burke, 860-253-6669

Marketing Communications Manager









Permalink: http://www.me-newswire.net/news/8885/en